July 15 (Reuters) - ProKidney Corp PROK.O:
PROKIDNEY ANNOUNCES ALIGNMENT WITH THE FDA ON THE ACCELERATED APPROVAL PATHWAY FOR RILPARENCEL
PROKIDNEY CORP - FDA CONFIRMS EGFR SLOPE AS SURROGATE ENDPOINT FOR RILPARENCEL IN PATIENTS WITH CKD & TYPE 2 DIABETES
PROKIDNEY CORP - TOPLINE DATA FOR ACCELERATED APPROVAL EXPECTED IN Q2 2027
PROKIDNEY CORP - FDA CONFIRMS PHASE 3 PROACT 1 STUDY CAN BE USED FOR BOTH ACCELERATED APPROVAL & FOR FULL APPROVAL
Source text: ID:nGNX5bQsS8
Further company coverage: PROK.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.